IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
107 hedge funds and large institutions have $1.52B invested in IGM Biosciences in 2020 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 14 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
114% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 14
40% more capital invested
Capital invested by funds: $1.08B → $1.52B (+$434M)
18% more funds holding
Funds holding: 91 → 107 (+16)
6.85% more ownership
Funds ownership: 60.54% → 67.39% (+6.9%)
0% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 32
84% less call options, than puts
Call options by funds: $5.37M | Put options by funds: $33.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$35.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$31.6M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$26.4M |
| 5 |
BlackRock
New York
|
+$18.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$24.1M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$14M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.87M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.25M |
| 5 |
Millennium Management
New York
|
-$1.56M |
IGMS Hedge Fund Activity: Q4 2020 in Review
107 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q4 2020, worth a combined $1.52B — up 40% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new IGMS positions and 14 closed out — a net gain of 16 holders — while 32 added to existing stakes and 32 trimmed.
The largest buyer was Artal Group, adding an estimated $35.9M. The largest seller was Janus Henderson Group, cutting an estimated $24.1M.
- 107 institutional investors held IGM Biosciences (IGMS) as of Q4 2020, up from 91 in Q3 2020.
- Funds reported $1.52B of IGM Biosciences stock for Q4 2020, up 40% quarter-over-quarter.
- 30 funds opened new IGM Biosciences positions in Q4 2020 and 14 closed out, a net change of +16 holders.
- The largest IGM Biosciences buyer in Q4 2020 was Artal Group, an estimated $35.9M added.
- The largest IGM Biosciences seller in Q4 2020 was Janus Henderson Group, an estimated $24.1M sold.
Based on aggregated 13F filings for Q4 2020.